Shennon Biotechnologies | LinkedIn (original) (raw)
Biotechnology Research
San Francisco, California 2,288 followers
Analyze, understand & manipulate immune cells on the single cell level to develop better treatments for human diseases
About us
ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput and accuracy, which resolves a key bottleneck in immunotherapy. We utilize the platform to functionally profile immune cells and their cognate antigens and apply this knowledge to develop more effective therapies against solid tumors and autoimmune diseases. Based in San Francisco next to UCSF Mission Bay, we are funded by DCVC, Foundation Capital and AV8. www.shennonbio.com
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
San Francisco, California
Type
Privately Held
Founded
2021
Specialties
Single cell functional profiling, Immunotherapy target discovery, Ultra high throughput analysis, More effective Immunotherapy, and Curative treatments for solid tumors
Locations
Employees at Shennon Biotechnologies
Updates
- We're #hiring a new Microfluidics Engineer in San Francisco, California. Apply today or share this post with your network.
- We're #hiring a new Join our Talent Pool! in San Francisco, California. Apply today or share this post with your network.
- Shennon Biotechnologies reposted this
Founder & CEO at Shennon Biotechnologies | PhD in Applied Physics | Former VC
1y Edited
We are #hiring a computational cancer biologist to join our interdisciplinary and highly dynamic team. We leverage our proprietary single cell platform to develop the next generation immunotherapies to treat solid tumors. If you know anyone who could be a good fit and is looking, please pass this info along. #immunotherapy #cancerbiology #bioinformaticsWe are also #hiring for a number of other roles at www.shennonbio.com/careers - We're #hiring a new Scientist in NGS & Cancer Genomics in San Francisco, California. Apply today or share this post with your network.